Back to search

Peptide record

TPDB11404

Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
33 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11404
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 iACP-DRLF AFP-GFuse Antifungipept CAFPdb ToxinPred 3.0
standard
No
A 33-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
VTCFCRRRGCASRERHIGYCRFGNTIYRLCCRR
Physicochemical Analysis
C166H271N63O42S6
DQKMPW
R
4013.73
10.26
10
1
9
+8
4.27
-0.524
47.27
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
3355
83.59
12
Residue Composition
number
1
A
9
R
1
N
0
D
6
C
1
E
0
Q
3
G
1
H
2
I
1
L
0
K
0
M
2
F
0
P
1
S
2
T
0
W
2
Y
1
V
Amino Acid Distribution
A: 1 R: 9 N: 1 D: 0 C: 6 E: 1 Q: 0 G: 3 H: 1 I: 2 L: 1 K: 0 M: 0 F: 2 P: 0 S: 1 T: 2 W: 0 Y: 2 V: 1
Chemical Descriptors
33
C166H271N63O42S6
4013.73
10.26
+8
4.27
-0.524
Evidence Records 22 records
Evidence 1 Activity

Activity

IC50
Antibacterial
0.6 µg/mL

Target

Streptococcus pyogenes

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against S. aureus (50% inhibition, IC50 0.8 ug/ml), S. pyogenes (IC50 0.6 ug/ml), E. faecalis (IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC5
Evidence 2 Activity

Activity

IC50
Antibacterial
0.4 µg/mL

Target

Enterococcus faecalis

Source & Reference

dbAMP DRAMP

Other

Active against S. aureus (50% inhibition, IC50 0.8 ug/ml), S. pyogenes (IC50 0.6 ug/ml), E. faecalis (IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50
Evidence 3 Activity

Activity

IC50
Antibacterial
0.8 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP DRAMP

Other

inhibition, IC50 0.8 ug/ml), S. pyogenes (IC50 0.6 ug/ml), E. faecalis (IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa
Evidence 4 Activity

Activity

IC50
Antibacterial
4.3 µg/mL

Target

Klebsiella oxytoca

Source & Reference

dbAMP DRAMP

Other

(IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1
Evidence 5 Activity

Activity

IC50
Antibacterial
46.2 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP

Other

50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1.8 ug/ml). UniProt P81465 : you c
Evidence 6 Activity

Activity

IC50
Antibacterial
4.6 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

e krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1.8 ug/ml). UniProt P81465 : you can view AlphaFold predicted st
Evidence 7 Activity

Activity

IC50
Antibacterial
1.8 µg/mL

Target

C. neoformans

Source & Reference

dbAMP DRAMP

Other

toca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1.8 ug/ml). UniProt P81465 : you can view AlphaFold predicted structure. Updated 7/2021 11/2024
Evidence 8 Activity

Activity

IC50
Antifungal
0.6 µg/mL

Target

Streptococcus pyogenes

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against S. aureus (50% inhibition, IC50 0.8 ug/ml), S. pyogenes (IC50 0.6 ug/ml), E. faecalis (IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC5
Evidence 9 Activity

Activity

IC50
Antifungal
0.4 µg/mL

Target

Enterococcus faecalis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against S. aureus (50% inhibition, IC50 0.8 ug/ml), S. pyogenes (IC50 0.6 ug/ml), E. faecalis (IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50
Evidence 10 Activity

Activity

IC50
Antifungal
0.8 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

inhibition, IC50 0.8 ug/ml), S. pyogenes (IC50 0.6 ug/ml), E. faecalis (IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa
Evidence 11 Activity

Activity

IC50
Antifungal
4.3 µg/mL

Target

Klebsiella oxytoca

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

(IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1
Evidence 12 Activity

Activity

IC50
Antifungal
46.2 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1.8 ug/ml). UniProt P81465 : you c
Evidence 13 Activity

Activity

IC50
Antifungal
4.6 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

e krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1.8 ug/ml). UniProt P81465 : you can view AlphaFold predicted st
Evidence 14 Activity

Activity

IC50
Antifungal
1.8 µg/mL

Target

C. neoformans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

toca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1.8 ug/ml). UniProt P81465 : you can view AlphaFold predicted structure. Updated 7/2021 11/2024
Evidence 15 Activity

Activity

IC50
Antiparasitic
0.6 µg/mL

Target

Streptococcus pyogenes

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
Active against S. aureus (50% inhibition, IC50 0.8 ug/ml), S. pyogenes (IC50 0.6 ug/ml), E. faecalis (IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC5
Evidence 16 Activity

Activity

IC50
Antiparasitic
0.4 µg/mL

Target

Enterococcus faecalis

Source & Reference

DRAMP

Other

Active against S. aureus (50% inhibition, IC50 0.8 ug/ml), S. pyogenes (IC50 0.6 ug/ml), E. faecalis (IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50
Evidence 17 Activity

Activity

IC50
Antiparasitic
0.8 µg/mL

Target

Escherichia coli

Source & Reference

DRAMP

Other

inhibition, IC50 0.8 ug/ml), S. pyogenes (IC50 0.6 ug/ml), E. faecalis (IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa
Evidence 18 Activity

Activity

IC50
Antiparasitic
4.3 µg/mL

Target

Klebsiella oxytoca

Source & Reference

DRAMP

Other

(IC50 0.4 ug/ml), E. coli (IC50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1
Evidence 19 Activity

Activity

IC50
Antiparasitic
46.2 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

DRAMP

Other

50 0.8 ug/ml), Salmonella serotype krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1.8 ug/ml). UniProt P81465 : you c
Evidence 20 Activity

Activity

IC50
Antiparasitic
4.6 µg/mL

Target

Candida albicans

Source & Reference

DRAMP

Other

e krefeld (IC50 1.2 ug/ml), K. oxytoca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1.8 ug/ml). UniProt P81465 : you can view AlphaFold predicted st
Evidence 21 Activity

Activity

IC50
Antiparasitic
1.8 µg/mL

Target

C. neoformans

Source & Reference

DRAMP

Other

toca (IC50 4.3 ug/ml), P. aeruginosa (IC50 46.2 ug/ml), C. albicans (IC50 4.6 ug/ml), and C. neoformans (IC50 1.8 ug/ml). UniProt P81465 : you can view AlphaFold predicted structure. Updated 7/2021 11/2024
Evidence 22 Activity

Activity

1% Hemolysis
Toxicity
<=6.3 µM
Hemolytic Cytotoxic
1% Hemolysis | <=6.3 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Characterisation and evaluation of synthetic antimicrobial peptides against Bacillus globigii, Bacillus anthracis and Burkholderia thailandensis. | Int J Antimicrob Agents | 2010